(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 April 2013 (04.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/049342 A1

(51) International Patent Classification:
A61K 39/155 (2006.01)

(21) International Application Number:
PCT/US2012/057546

(22) International Filing Date:
27 September 2012 (27.09.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/542,040	30 September 2011 (30.09.2011)	US
61/542,721	3 October 2011 (03.10.2011)	US
61/611,834	16 March 2012 (16.03.2012)	US
61/614,286	22 March 2012 (22.03.2012)	US

(71) Applicant *(for all designated States except US)*: **NOVAVAX, INC.** [US/US]; 9920 Belward Campus Drive, Rockville, Maryland 20850 (US).

(72) Inventors; and

(71) Applicants *(for US only)*: **SMITH, Gale** [US/US]; c/o NOVAVAX INC., 9920 Belward Campus Drive, Rockville, Maryland 20850 (US). **WU, Yingyun** [CN/US]; c/o NOVAVAX INC., 9920 Belward Campus Drive, Rockville, Maryland 20850 (US). **MASSARE, Michael** [US/US]; c/o NOVAVAX INC., 9920 Belward Campus Drive, Rockville, Maryland 20850 (US). **LIU, Ye** [CN/US]; c/o NOVAVAX INC., 9920 Belward Campus Drive, Rockville, Maryland 20850 (US).

(74) Agents: **TUSCAN, Michael S.** et al.; Cooley LLP, 777 6th Street, N.W., Suite 1100, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS

Figure 1



(57) Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. In one aspect, the invention provides recombinant RSV F proteins comprising modified or mutated amino acid sequences as compared to wild-type RSV F proteins. In general, these modifications or mutations increase the expression, reduce the cellular toxicity, and/or enhance the immunogenic properties of the RSV F proteins as compared to wild-type RSV F proteins. In certain exemplary embodiments, the RSV F proteins are human RSV F proteins.

WO 2013/049342 A1